XBiotech Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
| Accumulated Other | ||||||
|---|---|---|---|---|---|---|
| Number of · Common Stock · Comprehensive | ||||||
| Shares · Amount · Income · Accumulated deficit · Total | ||||||
| Balance at December 31, 2022 | 30,439 | $267,325 | $826 | $(27,749) | $240,402 | |
| Net loss | - | - | - | (24,557) | (24,557) | |
| Tender offer | (4) | (14) | - | - | (14) | |
| Foreign currency translation adjustment | - | - | (252) | - | (252) | |
| Reclassification of deferred tax assets | - | 574 | (574) | - | - | |
| Issuance of common stock under stock option plan | 1 | 5 | - | - | 5 | |
| Share-based compensation expense | - | 3,262 | - | - | 3,262 | |
| Balance at December 31, 2023 | 30,436 | 271,152 | - | (52,306) | 218,846 | |
| Net loss | - | - | - | (38,531) | (38,531) | |
| Issuance of common stock under stock option plan | 51 | 200 | - | - | 200 | |
| Share-based compensation expense | - | 1,753 | - | - | 1,753 | |
| Balance at December 31, 2024 | 30,487 | $273,105 | $ | - | $(90,837) | $182,268 |
See accompanying notes to condensed financial statements.
Consolidated Statements of Cash Flows
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.